Reversible cardiotoxicity with tyrosine kinase inhibitors

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 2, 2010, Pages 128-132

  Francis, Jawad ^a   Ahluwalia, Manmeet S ^b   Wetzler, Meir ^b   Wang, Eunice ^b   Paplham, Pamela ^b   Smiley, Shannon ^b   McCarthy, Philip L ^b   Cohen, I Larry ^b   Spangenthal, Edward ^b   Battiwalla, Minoo ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DOBUTAMINE; ETOPOSIDE; FLUDARABINE; HYPERTENSIVE FACTOR; IMATINIB; MELPHALAN; MITOXANTRONE; NICARDIPINE; NILOTINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CARDIOMYOPATHY; CARDIOTOXICITY; CASE REPORT; CENTRAL NERVOUS SYSTEM LEUKEMIA; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GRAFT VERSUS HOST REACTION; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MURMUR; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; RECURRENT INFECTION; RESUSCITATION; SEPTIC SHOCK; WHOLE BODY RADIATION;

ADULT; CARDIOTOXINS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77749236976     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007;110:1178-1186.
2. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332-344.
3. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92: 1556-1564.
4. Wetzler M, Stock W, Donohue KA, et al. Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) CALGB study 10001. Blood (ASH Annual Meeting Abstracts). 2007;110: Abstract 2869.
5. Baer MR, Ford LA, Bundy BN, et al. Randomized trial of GM-CSF and G-CSF following high-dose cytarabine and mitoxantrone chemotherapy for relapsed and refractory acute leukemia. Blood (ASH Annual Meeting Abstracts). 2006;108: Abstract 4574.
6. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-916.
7. Rosti G, Martinelli G, Baccarani M. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.' Nat Med. 2007;13:15; author reply 15-16.
8. Atallah E, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med. 2007;13:14; author reply 15-16.
9. Park YH, Park HJ, Kim BS, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 2006;243:16-22.
10. Perik PJ, Rikhof B, de Jong FA, Verweij J, Gietema JA, van der Graaf WT. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol. 2008;19:359-361.
11. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
12. Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res. 2006;30:1201-1205.
13. Ribeiro AL, Marcolino MS, Bittencourt HN, et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008;32:1809-1814.
14. Tiribelli M, Colatutto A, Marin L, et al. Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. Am J Hematol. 2008;83: 517-518.
15. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26: 3777-3784.
16. Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol. 2007;25:3635-3643.
17. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545-550.
18. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
19. Will Y, Dykens JA, Nadanaciva S, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106:153-161.
20. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204-5212.
21. Distler JH, Distler O. Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? Ann Rheum Dis. 2007;66:836.
22. Barton JC, Jones SC, Lamberth WC, Reymann MT, Scott VC. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol. 2002;71:139-140.
23. Breccia M, D'Elia GM, D'Andrea M, Latagliata R, Alimena G. Pleuralpericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol. 2005;74:89-90.
24. Sprycel (dasatinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; June 2009.
25. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-2019.
26. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233-1237.FA